Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Ontario Teachers Pension Plan Board

Ontario Teachers Pension Plan Board lowered its holdings in Moderna, Inc. (NASDAQ:MRNA) by 31.6% in the 3rd quarter, Holdings Channel.com reports. The fund owned 15,701 shares of the company’s stock after selling 7,259 shares during the quarter. Ontario Teachers Pension Plan Board’s holdings in Moderna were worth $1,049,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in MRNA. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Moderna in the second quarter worth $26,000. Family Firm Inc. purchased a new position in shares of Moderna in the second quarter valued at $33,000. Bank & Trust Co purchased a new position in shares of Moderna in the second quarter valued at $36,000. Hanseatic Management Services Inc. purchased a new position in shares of Moderna in the second quarter valued at $48,000. Finally, Plato Investment Management Ltd boosted its stake in shares of Moderna by 230.4% in the second quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock valued at $49,000 after purchasing an additional 288 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Wall Street Analyst Weigh In

MRNA has been the subject of several analyst reports. Deutsche Bank Aktiengesellschaft upgraded shares of Moderna from a “sell” rating to a “hold” rating and decreased their target price for the company from $85.00 to $80.00 in a research note on Wednesday, August 7th. UBS Group reduced their price objective on shares of Moderna from $140.00 to $108.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. JPMorgan Chase & Co. reduced their price objective on shares of Moderna from $70.00 to $59.00 and set an “underweight” rating on the stock in a research note on Monday, November 4th. The Goldman Sachs Group reduced their price objective on shares of Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a research note on Monday, September 16th. Finally, HSBC upgraded shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price objective on the stock in a research note on Monday. Three equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $84.00.

Moderna Trading Down 0.9 %

NASDAQ:MRNA opened at $36.94 on Thursday. Moderna, Inc. has a twelve month low of $35.80 and a twelve month high of $170.47. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. The company has a 50-day moving average of $56.98 and a 200-day moving average of $95.46.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. During the same period last year, the company posted ($1.39) earnings per share. The business’s revenue for the quarter was up 3.8% on a year-over-year basis. Equities analysts expect that Moderna, Inc. will post -9.44 earnings per share for the current year.

Insider Activity at Moderna

In related news, CFO James M. Mock sold 1,321 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the transaction, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at approximately $682,754. This trade represents a 13.32 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In the last 90 days, insiders sold 2,930 shares of company stock valued at $217,170. Insiders own 15.70% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.